Developing Pediatric Clinical Pharmacologists for the Advancement of Therapeutics

 描述（由申请人提供）：虽然近年来成人药物治疗取得了巨大进展，但将这些新疗法的益处扩展到婴儿和儿童仍然是一个重大挑战。药代动力学、药效学、疾病表现和进展方面的重要发育变化都阻碍了成人治疗方法直接转化为儿科治疗方法。儿科临床药理学学科提供发育生理学方面的必要培训，以利用现有知识并指导婴儿和儿童的合理治疗。然而，目前接受过临床药理学正规培训的药理学家和儿科专科医生人数较少，而且年龄偏大。由加州大学圣地亚哥分校（UCSD）儿科系领导的T32奖学金计划，名为“为治疗学的进步发展儿科临床药理学家”（DPCPAT），将提供儿科临床药理学的前沿研究培训和指导，使我们的学员成为儿科学术研究人员队伍中的领导者。加州大学圣地亚哥分校的生物医学研究界长期以来一直享有卓越的声誉，目前在美国所有机构的NIH研究资金中排名前5位。值得注意的是，在过去的5-10年里，UCSD儿科系及其研究使命的学术扩展令人印象深刻，再加上Rady儿童医院圣地亚哥（RCHSD）和医学和药学的UCSD学校之间的协同关系的固化。我们将提供充分的证据，证明在UCSD创建DPCPAT培训计划的时机从未如此之好，而且我们的研究培训环境和教师无论如何都是真正的世界一流。DPCPAT计划的总体目标是为儿科医生科学家准备持续，独立和高效研究的终身挑战。大卫布伦纳博士，院长和健康科学副校长，杰克狄克逊博士，副校长科学事务，加布里埃尔哈达德博士，儿科系主任和博士詹姆斯McKerrow，药学院院长，提供了UCSD机构承诺信我们提出的DPCPAT，确认该计划的核心重要性，以医学UCSD学院的学术使命。我们的DPCAT的主要目标如下：（1）增加儿科临床药理学家和临床科学家参与临床药理学研究的数量，应用于儿童健康;（2）吸引优秀的年轻儿科临床医生到UCSD，并通过临床药理学方法扩大他们的翻译能力;（3）在世界一流的导师指导下促进DPCAT学员的职业发展;（4）培养女性和少数民族研究人员在儿科治疗学方面的早期职业生涯。凭借我们令人印象深刻的导师团队以及出色的培训记录，UCSD DPCPAT研究员将成为儿科临床药理学的明日领导者。

 DESCRIPTION (provided by applicant): While tremendous advances in pharmacotherapy for adults have been achieved in recent years, expanding the benefits of these new therapies to infants and children remains a significant challenge. Important developmental changes in pharmacokinetics, pharmacodynamics, disease presentation and progression all impede direct translation of adult therapeutics into pediatrics. The discipline of pediatric clinical pharmacolog provides necessary training in developmental physiology to leverage existing knowledge and guide rational therapeutics for infants and children. However, the current pool of pharmacologists and pediatric sub- specialists with formal training in clinical pharmacology is both small and aging. This T32 Fellowship Program led by the Department of Pediatrics at the University of California, San Diego (UCSD), entitled Developing Pediatric Clinical Pharmacologists for the Advancement of Therapeutics (DPCPAT), will provide cutting-edge research training and mentorship in pediatric clinical pharmacology, enabling our trainees to emerge as leaders among the ranks of pediatric academic investigators. The biomedical research community at UCSD has a long- established reputation of excellence, and now ranks in the top 5 in NIH research funding of all US institutions. Notably, the last 5-10 years have witnessed an impressive academic expansion within the UCSD Department of Pediatrics and its research mission, coupled with the solidification of the synergistic relationship among Rady Children's Hospital San Diego (RCHSD) and the UCSD Schools of Medicine and Pharmacy. We will provide ample evidence that the timing for creation of the DPCPAT training program at UCSD has never been better, and that our research training environment and faculty are truly world class by any measure. The overarching goal of the DPCPAT program will be to prepare Pediatric Physician-Scientists for the lifelong challenges of a sustained, independent and highly productive research. Dr. David Brenner, Dean and Vice Chancellor for Health Sciences, Dr. Jack Dixon, Associate Vice Chancellor for Scientific Affairs, Dr. Gabriel Haddad, Chair of the Department of Pediatrics and Dr. James McKerrow, Dean of the School of Pharmacy, have provided letters of UCSD institutional commitment to our proposed DPCPAT, confirming the central importance of this Program to the academic mission of the UCSD School of Medicine. The key objectives of our DPCAT are as follows: (1) To increase the number Pediatric clinical pharmacologists and Clinician-Scientists engaged in clinical pharmacology research as applied to child health; (2) to attract outstanding young pediatric clinicians to UCSD and to expand their translational capacity through clinical pharmacology methods; (3) to facilitate career development of DPCAT trainees under the guidance of world class, established investigator-faculty mentors; and (4) to cultivate the early careers of women and minority investigators in pediatric therapeutics. With our impressive group of mentors with outstanding training track records, UCSD DPCPAT Fellows will be poised to be tomorrow's leaders in pediatric clinical pharmacology.